Jupiter, Florida – October 16, 2026 -- Myosin Therapeutics will present its first-in-class cancer candidate MT-125 at BioFuture 2026 in New York City on October 27–28, seeking investors and pharmaceutical partners to fund an extension into two additional treatment-resistant cancers.
CEO Courtney Miller joins oncology panel on October 27
Chief Executive Officer Courtney Miller, PhD, will speak on the panel "Beyond the Cure: The Brave New World of Revolutionary Cancer Therapeutics." The session covers next-generation cell therapies, AI-enabled cancer drug discovery, precision medicines and advanced therapeutic platforms. Participating CEOs will introduce their companies, followed by a moderated round-robin discussion.
Chief Medical Officer Karen Smith, MD, PhD, MBA, LLM, will join Miller for investor and strategic partner meetings throughout the conference.
NCI showcase selection precedes a run of investor events
The invitation follows Myosin's selection as a 2026–2027 National Cancer Institute SBIR Investor Initiatives Showcase Company. The company recently presented at Biocom California's Global Partnering & Investor Conference, the BIO Investor Forum and BioFlorida's South Florida Life Sciences Showcase.
BioFuture, produced by Demy-Colton, expects 500+ global attendees, 100+ speakers and 50+ presenting companies across its Therapeutic Spotlight Panels and Seed Showcase, with one-to-one meetings arranged through a partnering system.
MT-125 holds FDA Orphan Drug and Fast Track designations
MT-125 is a non-muscle myosin inhibitor designed to disrupt the mechanical dependencies of cancer cells, leading to tumor cell death. The FDA has granted it Orphan Drug Designation for malignant gliomas and Fast Track Designation for glioblastoma (GBM). The underlying science is supported by two peer-reviewed publications in Cell.
The NCI-supported STAR-GBM trial (NCT07185880) is enrolling patients with newly diagnosed, MGMT unmethylated GBM at Mayo Clinic sites in Florida, Arizona and Minnesota. Miller said the trial is advancing toward its Phase 2 dose expansion stage, and that the company plans to extend MT-125 into two additional treatment-resistant cancers. She contrasted the approach with therapies that target signaling pathways tumors learn to bypass.